Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 2014. The report serves as a notification to the market regarding the company's total voting rights and capital structure in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a corporate governance notification rather than a financial performance report.
Material Changes
The filing details the company's issued share capital as of May 30, 2014:
- Total Issued Shares: 5,350,668,768 Ordinary Shares of 25p each.
- Treasury Shares: 494,090,214 Ordinary Shares.
- Total Voting Rights: 4,856,578,554.
No material changes to financial performance or operational strategy are disclosed in this text.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The primary purpose is to provide the denominator for shareholders to calculate notification thresholds under the Financial Conduct Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of voting rights (4,856,578,554) against the latest share register.
- Confirm the number of shares held in Treasury (494,090,214) to ensure accurate calculation of free float.
- Check subsequent filings for actual financial performance data, as this 6-K does not contain earnings results.